Oral administration of recombinant Neisseria meningitidis PorA genetically fused to H. pylori HpaA antigen increases antibody levels in mouse serum, suggesting that PorA behaves as a putative adjuvant

References

• Rosenstein NE, Bradleya MD, Perkins MD, Stephens DS, Popovic T, Hughes MD. Meningococcal Disease. N Engl J Med 2001; 344:1378-88; PMID:11333996; http://dx.doi.org/10.1056/NEJM200105033441807
   PubMed Web of Science ®Google Scholar
• Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009; 27 (Suppl. 2):B51-63; PMID:19477562
   PubMed Web of Science ®Google Scholar
• Swartley JS, Marfin AA, Edupuganti S, Liu LJ, Cieslak P, Perkins B, Wenger JD, Stephens DS. Capsule switching of Neisseria meningitidis. Proc Natl Acad Sci USA 1997; 94:271-6.; PMID: 8990198
   PubMed Web of Science ®Google Scholar
• Halperin SA, Bettinger JA, Greenwood B, Harrison LH, Jelfs J, Ladhani SN, McIntyre P, Ramsay ME, Sáfadi MA. The changing and dynamic epidemiology of meningococcal disease. Vaccine 2012; 30 Suppl 2:B26-36; PMID:22178525; http://dx.doi.org/10.1016/j.vaccine.2011.12.032
   PubMed Web of Science ®Google Scholar
• Snape MD, Pollard AJ. Meningococcal polysaccharide-protein conjugate vaccines. Lancet Infect Dis. 2005; 5:21-30; PMID:15620558; http://dx.doi.org/10.1016/S1473-3099(04)01251-4
   PubMed Web of Science ®Google Scholar
• Girard MP, Preziosi M-P, Aguado M-T, Kieny MP. A review of vaccine research and development: Meningococcal disease. Vaccine 2006; 24:4692-700; PMID:16621189; http://dx.doi.org/10.1016/j.vaccine.2006.03.034
   PubMed Web of Science ®Google Scholar
• Richmond P, Borrow R, Goldblatt D, Findlow J, Martin S, Morris R, Cartwright K, Miller E. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis 2001; 183:160-3; PMID:11078484; http://dx.doi.org/10.1086/317646
   PubMed Web of Science ®Google Scholar
• Pichichero M, Casey J, Blatter M, Rothstein E, Ryall R, Bybel M, Gilmet G, Papa T. Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y,W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children. Pediatr Infect Dis J 2005; 24:57-62; PMID:15665711
   PubMed Web of Science ®Google Scholar
• Pace D, Pollard AJ, Messonier NE. Quadrivalent meningococcal conjugate vaccines. Vaccine. 2009; 27 Suppl 2:B30-41; PMID:19477560; http://dx.doi.org/10.1016/j.vaccine.2009.05.003
   PubMedGoogle Scholar
• Griffiss JM, Yamasaki R, Estabrook M, Kim JJ. Meningococcal molecular mimicry and the search for an ideal vaccine. Trans R Soc Trop Med Hyg 1991; 85(Suppl 1):32-6; PMID:1725072
   PubMedGoogle Scholar
• Zimmer SM, Stephens DS. Serogroup B meningococcal vaccines. Curr Opin Investig Drugs 2006; 7:733-9; PMID:16955685
   PubMed Web of Science ®Google Scholar
• Panatto D, Amicizia D, Lai PL, Gasparini R. Neisseria meningitidis B vaccines. Expert Rev Vaccines 2011; 10:1337-51
   PubMed Web of Science ®Google Scholar
• Santolaya ME, O'Ryan ML, Valenzuela MT, Prado V, Vergara R, Muñoz A, Toneatto D, Graña G, Wang H, Clemens R., et al., Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012; 379: 617-24; PMID:22260988; http://dx.doi.org/10.1016/S0140-6736(11)61713-3
   PubMed Web of Science ®Google Scholar
• Findlow J, Borrow R, Snape MD, Dawson T, Holland A, John TM, Evans A, Telford KL, Ypma E, Toneatto D, et al., Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 2010; 51:1127-37; PMID:20954968
   PubMed Web of Science ®Google Scholar
• Pizza M, Scarlato V, Masignani V, Giuliani MM, Aricò B, Comanducci M, Jennings GT, Baldi L, Bartolini E, Capecchi B, et al. Identification of vaccine candidates against serogroup B by whole-genome sequencing. Science 2000; 287:1816-20; PMID:10710308; http://dx.doi.org/10.1126/science.287.5459.1816
   PubMed Web of Science ®Google Scholar
• Moe GR, Dave A, Granoff DM. Molecular analysis of anti-N-propionyl Neisseria meningitidis group B polysaccharide monoclonal antibodies. Mol Immunol 2005; 43:1424-31; PMID:16140379
   PubMed Web of Science ®Google Scholar
• Giuliani M, Adu-Bobie J, Comanducci M, Aricò B, Savino S, Santini L, Brunelli B, Bambini S, Biolchi A, Capecchi B, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 2006; 103:10834-9.
   Google Scholar
• Jodar L, Feavers MI, Saliisbury D, Granoff DM. Development of vaccines against meningococcal disease. Lancet 2002; 359:1499-508; PMID:11988262; http://dx.doi.org/10.1016/S0140-6736(02)08416-7
   PubMed Web of Science ®Google Scholar
• Boslego J, Garcia J, Cruz C, Zollinger W, Brandt B, Ruiz S, Martinez M, Arthur J, Underwood P, Silva W, et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Vaccine 1995; 13:821-9; PMID:7483804; http://dx.doi.org/10.1016/0264-410X(94)00037-N
   PubMed Web of Science ®Google Scholar
• De Moraes JC, Perkins BA, Camargo MC, Hidalgo NT, Barbosa HA, Sacchi CT, Gral IL, Gattas VL, Vasconcelos HG, Plikaytis BD, et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 1992; 340:1074-8; PMID:1357461; http://dx.doi.org/10.1016/0140-6736(92)93086-3
   PubMed Web of Science ®Google Scholar
• O’Hallahan J, Lennon D, Oster P. The strategy to control New Zealand's epidemic of group B meningococcal disease. Pediatr Infect Dis J 2004; 23:S293-8; PMID:15597072
   PubMedGoogle Scholar
• Oster P, Lennon D, O’Hallahan J, Mulholland K, Reid S, Martin N. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 2005; 23:2191-6.
   Google Scholar
• Holst J, Feiring B, Næss LM, Norheim G, Kristiansen P, Høiby EA, Bryn K, Oster P, Costantino P, Taha M-K, e al. The concept of “tailor-made”, protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine 2005; 23:2191-6
   PubMed Web of Science ®Google Scholar
• Derrick JP, Urwin R, Suker J, Feavers IM, Maiden IM. MCJ. Structural and evolutionary inference from molecular variation in Neisseria porins. Infect Immun 1999; 67:2406-13; PMID:10225902
   PubMed Web of Science ®Google Scholar
• Idanpaan-Heikkila I, Wahlstrom E; Nurminen M, Makela HP, Sarvas M. The Neisseria meningitidis outer membrane protein P1 produced in Bacillus subtilis and reconstituted into phospholipid vesicles elicits antibodies to native P1 epitopes. Microb Pathog 1995; 18:423-36
   PubMed Web of Science ®Google Scholar
• Van der Voort ER, Van der Ley P, Van der Biezen J, Steohen G, Tunnela O, Van der Diejken H, Kuipers B, Poolman J. Specificity of human bactericidal antibodies against PorA P1.7,16 Induced with a hexavalent meningococcal outer membrane vesicle vaccine. Infect Immun 1996; 64:2745-51; PMID:8698504
   PubMed Web of Science ®Google Scholar
• Neisseria PorA typing [Internet]. UK: Keith Jolley and sited at the University of Oxford. 2010 – [cited 2014 september 12]. Available from: http://pubmlst.org/neisseria/PorA/
   Google Scholar
• Luijkx TA, van Dijken H, Hamstra H-J, Kuipers B, van der Ley P, van Alphen L, van den Dobbelsteen G. Relative immunogenicity of PorA subtypes in a multivalent Neisseria meningitidis vaccine is not dependent on presentation form. Infect Immun 2003; 71: 6367-71; PMID:14573657; http://dx.doi.org/10.1128/IAI.71.11.6367-6371.2003
   PubMed Web of Science ®Google Scholar
• Holst J. Strategies for development of universal vaccines against meningococcal serogroup B disease. Hum Vaccines 2007; 3: 290-4; PMID:17712231
   PubMed Web of Science ®Google Scholar
• van den Dobbelsteen GP, van Dijken HH, Pillai S, van Alphen L. Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs. Vaccine 2007; 25: 2491-6; PMID:17023098; http://dx.doi.org/10.1016/j.vaccine.2006.09.025
   PubMed Web of Science ®Google Scholar
• Kaaijk P, van Straaten I, van de Waterbeemd B, Boot EPJ, Levels LMAR, van Dijken HH, van den Dobbelsteen GPJM. Preclinical safety and immunogenicity evaluation of a nonavalent PorA native outer membrane vesicle vaccine against serogroup B meningococcal disease. Vaccine 2013; 31:1065-71; PMID:23273968; http://dx.doi.org/10.1016/j.vaccine.2012.12.031
   PubMed Web of Science ®Google Scholar
• Cartwright K, Morris R, Rümke H, Fox A, Borrow R, Begg N, Richmond P, Poolman J. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine 1999; 17:2612-9; PMID:10418910; http://dx.doi.org/10.1016/S0264-410X(99)00044-4
   PubMed Web of Science ®Google Scholar
• Longworth E, Borrow R, Goldblatt D, Balmer P, Dawson M, Andrews N, Miller E, Cartwright K. Avidity maturation following vaccination with a meningococcal recombinant hexavalent PorA OMV vaccine in UK infants. Vaccine 2002; 20:2592-6; PMID:12057617; http://dx.doi.org/10.1016/S0264-410X(02)00151-2
   PubMed Web of Science ®Google Scholar
• Arigita C, Kersten GFA, Hazendonk T, Hennink WE, Crommelin DJA, Jiskoot W. Restored functional immunogenicity of purified meningococcal PorA by incorporation into liposomes. Vaccine 2003; 21: 950-60; PMID:12547608; http://dx.doi.org/10.1016/S0264-410X(02)00546-7
   PubMed Web of Science ®Google Scholar
• Pinto VB, Moran EE, Cruz F, Wang X-M, Fridman A, Zollinger WD, Przysiecki CT, Burden R. An experimental outer membrane vesicle vaccine from N. meningitidis serogroup B strains that induces serum bactericidal activity to multiple serogroups. Vaccine 2011; 29:7752-8
   PubMed Web of Science ®Google Scholar
• Morein B, Sundquist B, Höglund S, Dalsgaard K, Ostehaus A. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 1984; 308:457-60; PMID:6709052; http://dx.doi.org/10.1038/308457a0
   PubMed Web of Science ®Google Scholar
• Sjölander A, Cox JC. Uptake and adjuvant activity of orally delivered saponin and ISCOM vaccines. Adv Drug Del Rev 1998; 34:321-38; PMID:10837684ND; http://dx.doi.org/10.1016/S0169-409X(98)00046-5
   PubMed Web of Science ®Google Scholar
• Peeters CC, Claassen IJ, Schuller M, Kersten GF, Van der Voort EM, Poolman JT. Immunogenicity of various presentation forms of PorA outer membrane protein of Neisseria meningitidis in mice. Vaccine 1999; 17:2702-12; PMID:10418921
   PubMed Web of Science ®Google Scholar
• Humphries HE, Williams JN, Christodoulides M, Heckels J. Recombinant meningococcal PorA protein, expressed using a vector system with potential for human vaccination, induces a bactericidal immune response. Vaccine 2004; 22:5164-9; PMID:15063582; http://dx.doi.org/10.1016/j.vaccine.2003.09.042
   PubMedGoogle Scholar
• Humphries HE, Williams JN, Blackstone R, Jolley KA, Yuen HM, Christodoulides M, Heckels JE. Multivalent liposome-based vaccines containing different serosubtypes of PorA protein induce cross-protective bactericidal immune responses against Neisseria meningitidis. Vaccine 2006; 24:36-44; PMID:16105711
   PubMed Web of Science ®Google Scholar
• Lövgren K, Morein B. The requirement of lipids for the formation of immunostimulating complexes (iscoms). Biotechnol Appl Biochem 1988; 10:161-72; PMID:2838046
   PubMed Web of Science ®Google Scholar
• Morein B, Bengtsson LK. Immunomodulation by Iscoms, immunostimulating complexes. Methods (San Diego, Calif.) 1999; 19:94-102; PMID:10525444
   PubMed Web of Science ®Google Scholar
• Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol 2008; 30:23-32; PMID:19059004
   PubMed Web of Science ®Google Scholar
• Organización Panamericana de la Salud. Informe regional de SIREVA II 2000-2005. 2005: 108-14.
   Google Scholar
• Saunders NB, Zollinger WD, Rao VB. A rapid and sensitive PCR strategy employed for amplification and sequencing of porA from a single colony-forming unit of Neisseria meningitidis. Gene 1993; 137:153-62; PMID:8299943
   PubMed Web of Science ®Google Scholar
• Sacchi CT, Lemos AP, Brandt ME, Whitney AM, Melles CE, Solari CA, Frasch CE, Mayer LW. Proposed standardization of Neisseria meningitidis PorA variable-region typing nomenclature. Clin Diagn Lab Immunol. 1998; 5(6):845-55; PMID:9801347
   PubMedGoogle Scholar
• Rokbi B, Renauld-Mongenie G, Mignon M, Danve B, Poncet D, Chabanel C, Caugant DA, Quentin-Millet MJ. Allelic diversity of the two transferrin binding protein B gene isotypes among a collection of Neisseria meningitidis strains representative of serogroup B disease: implication for the composition of a recombinant TbpB-based vaccine. Infect Immun. 2000; 68(9):4938-47; PMID:10948108; http://dx.doi.org/10.1128/IAI.68.9.4938-4947.2000
   PubMed Web of Science ®Google Scholar
• Kashiwagi Y, Maeda M, Kawashima H, Nakayama T. Inflammatory responses following intramuscular and subcutaneous immunization with aluminum-adjuvanted or non-adjuvanted vaccines. Vaccine. 2014 5; 32(27):3393-401; PMID:24768634; http://dx.doi.org/10.1016/j.vaccine.2014.04.018
   PubMedGoogle Scholar
• Liu X, Wetzler LM, Massari, P. The PorB porin from commensal Neisseria lactamica induces Th1 and Th2 immune responses to ovalbumin in mice and is a potential immune adjuvant. Vaccine 2008; 26:786-96; PMID:18191311; http://dx.doi.org/10.1016/j.vaccine.2007.11.080
   PubMed Web of Science ®Google Scholar
• Perrett KP, Pollard AJ. Towards an improved serogroup B Neisseria meningitidis vaccine. Expert Opin Biol Ther 2005; 5:1611-25; PMID:16318425
   PubMed Web of Science ®Google Scholar
• Sorhouet PC, Regueira M, Mollerach M. PorA types in Neisseria meningitidis serogroup B isolated in Argentina from 2001 to 2003: implications for the design of an outer membrane protein-based vaccine. J Med Microbiol 2008; 57:338-42PMID:18287297; http://dx.doi.org/10.1099/jmm.0.47631-0
   PubMedGoogle Scholar
• Zhu D, Williams JN, Rice J, Stevenson FK, Heckels JE, Christodoulides M. A DNA fusion vaccine induces bactericidal antibodies to a peptide epitope from the PorA porin of Neisseria meningitidis. Infect Immun 2008; 76:334-8; PMID:17967859
   PubMed Web of Science ®Google Scholar
• O’Dwyer CA, Reddin K, Martin D, Taylor SC, Gorringe AR, Hudson MJ, Brodeur BR, Langford PR, Kroll JS. Expression of heterologous antigens in commensal Neisseria spp: preservation of conformational epitopes with vaccine potential. Infect Immun 2004; 72:6511-8; PMID:15501782
   PubMed Web of Science ®Google Scholar
• Danve B, Lissolo L, Mignon M, Dumas P, Colombani S, Schryvers AB, Quentin-Millet MJ. Transferrin-binding proteins isolated from Neisseria meningitidis elicit protective and bactericidal antibodies in laboratory animals. Vaccine 1993; 11:1214-20; PMID:8256502
   PubMed Web of Science ®Google Scholar
• West D, Reddin K, Matheson M, Heath R, Funnell S, Hudson M, Robinson A, Gorringe A. Recombinant Neisseria meningitidis transferrin binding protein A protects against experimental meningococcal infection. Infect Immun 2001; 69:1561-7; PMID:11179327
   PubMed Web of Science ®Google Scholar
• Pillai S, Howell A, Alexander K, Bentley BE, Jiang HQ, Ambrose K, Zhu D, Zlotnick G. Outer membrane protein (OMP) based vaccine for Neisseria meningitidis serogroup B. Vaccine 2005; 23:2206-9; PMID:15755596
   PubMed Web of Science ®Google Scholar
• Welsch JA, Moe GR, Rossi R, Adu-Bobie J, Rappuoli R, Granoff DM. Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J Infect Dis 2003; 188:1730-40; PMID:14639545
   PubMed Web of Science ®Google Scholar
• Comanducci M, Bambini S, Caugant DA, Mora M, Brunelli B, Capecchi B, Ciucchi L, Rappuoli R, Pizza M. NadA diversity and carriage in Neisseria meningitidis. Infect Immun 2004; 72: 4217-23; PMID:15213166
   PubMed Web of Science ®Google Scholar
• Holst J, Martin D, Arnold R, Huergo CC, Oster P, O’Hallahan J, Rosenqvist E. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 2009; 27(Supp 2):B3-B12; PMID:19481313; http://dx.doi.org/10.1016/j.vaccine.2009.04.071
   PubMedGoogle Scholar
• de Kleijn E, van Eijndhoven L, Vermont C, Kuipers B, van Dijken H, Rümke H, de Groot R, van Alphen L, van den Dobbelsteen G. Serum bactericidal activity and isotype distribution of antibodies in toddlers and schoolchildren after vaccination with RIVM hexavalent PorA vesicle vaccine. Vaccine 2001; 20:352-8; PMID:11672897; http://dx.doi.org/10.1016/S0264-410X(01)00371-1
   PubMed Web of Science ®Google Scholar
• Gentle IE, Burri L, Lithgow T. Molecular architecture and function of the Omp85 family of proteins. Mol Microbiol 2005; 58:1216-25; PMID:16313611; http://dx.doi.org/10.1111/j.1365-2958.2005.04906.x
   PubMed Web of Science ®Google Scholar
• Werner J, Misra R. Yae T (Omp85) affects the assembly of lipid-dependent and lipid-independent outer membrane proteins of Escherichia coli. Mol Microbiol 2005; 57:1450-9; PMID:NOT_FOUND
   PubMed Web of Science ®Google Scholar
• Robert V, Volokhina EB, Senf F, Bos MP, Van Gelder P, Tommassen J. Assembly factor Omp85 recognizes its outer membrane protein substrates by a species-specific C-terminal motif. PloS Biol 2006; 4:e377; PMID:17090219
   PubMedGoogle Scholar
• Jansen C, Wiese A, Reuvsaet L, Dekker N, de Cook H. Seydel U, Tommassen J. Biochemical and biophysical characterization of in vitro folded outer membrane porin PorA of Neisseria meningitidis. Biochim Biophys Acta 2000; 1464:284-98; PMID:10727615
   PubMed Web of Science ®Google Scholar
• Næss L, Tanja N, Aarvaka A, Oftung F, Hoiby E, Sandin R, Michaelsen TE. Human IgG subclass responses in relation to serum bactericidal and opsonic activities after immunization with three doses of the Norwegian serogroup B meningococcal outer membrane vesicle vaccine. Vaccine 1999; 17:754-64; http://dx.doi.org/10.1016/S0264-410X(98)00259-X
   PubMed Web of Science ®Google Scholar
• Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection serum bactericidal antibody activity. Vaccine 2005; 23:2222-7; PMID:15755600; http://dx.doi.org/10.1016/j.vaccine.2005.01.051
   PubMed Web of Science ®Google Scholar
• Santos GF, Deck R, Donnelly J, Blackwelder W, Granoff DM. Importance of complement source in measuring meningococcal bactericidal titers. Clin Diag Lab Immunol 2001; 8:616-23; PMID:11329468
   PubMedGoogle Scholar
• Kees LM, Franken KL, Hiemstra HS, van Meijgaarden KE, Subronto Y, Den Hartigh J, Ottenhoff TH, Drijfhout JW. Purification of His-tagged proteins by immobilized chelate affinity chromatography: The benefits from the use of organic solvent. Proc Natl Acad Sci USA 2000; 97:2029-34.
   PubMed Web of Science ®Google Scholar
• Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-54; PMID:942051
   PubMedGoogle Scholar
• Bengtsson LK, Sjölander A. Adjuvant activity of iscoms; effect of ratio and co-incorporation of antigen and adjuvant. Vaccine 1996; 14:753-60; PMID:8817821
   PubMed Web of Science ®Google Scholar
• Gu Q, Song D, Zhu M. Oral vaccination of mice against Helicobacter pylori with recombinant Lactococcus lactis expressing urease subunit B. FEMS. Immunol Med Microbiol 2009; 56:197-203; PMID:19453750
   PubMed Web of Science ®Google Scholar
• Scavone P, Miyoshi A, Rial A, Chabalgoity A, Langella P, Azevedo V, Zunino P. Intranasal immunisation with recombinant Lactococcus lactis displaying either anchored or secreted forms of Proteus mirabilis MrpA fimbrial protein confers specific immune response and induces a significant reduction of kidney bacterial colonisation in mice. Microbes Infect 2007; 9:821-8; PMID:17540603
   PubMed Web of Science ®Google Scholar
• Hoiby E, Rosenqvist E, Froholm L, Bjune G, Fiering B, Nokleby H, Ronnild E. Bactericidal antibodies after vaccination with the Norwegian meningococcal serogoup B outer membrane vesicle vaccine: a brief survey. NIPH Ann 1991; 14:147-56; PMID:1812429
   PubMedGoogle Scholar
• Wetzler LM. Innate immune function of the neisserial porins and the relationship to vaccine adjuvant activity. Future Microbiol 2010; 5:749-58; PMID:20441547; http://dx.doi.org/10.2217/fmb.10.41
   PubMed Web of Science ®Google Scholar
• Burke JM, Gangley-Leal LM, Khatri A, Wetzler LM. Neisseria meningitidis PorB, a TLR2 ligand, induces an antigen-specific eosinophil recall response: potential adjuvant for helminth vaccines? J Immunol 2007; 179:3222-30; PMID:17709538
   PubMed Web of Science ®Google Scholar
• Tanabe M, Nimigean CM, Iverson TM. Structural basis for solute transport, nucleotide regulation, and immunological recognition of Neisseria meningitidis PorB. Proc Natl Acad Sci USA 2010; 107:6811-6; PMID:20351243; http://dx.doi.org/10.1073/pnas.0912115107
   PubMed Web of Science ®Google Scholar
• Massari P, Visintin A, Gunawardana J, Halmen KA, King CA, Golenbock DT, Wetzler LM. Meningococcal porin PorB binds to TLR2 and requires TLR1 for signaling. J Immunol. 2006; 176:2373-80; PMID:16455995; http://dx.doi.org/10.4049/jimmunol.176.4.2373
   PubMed Web of Science ®Google Scholar
• Massari P, Ho Y, Wetzler LM. Neisseria meningitidis porin PorB interacts with mitochondria and protects cells from apoptosis. Proc Natl Acad Sci USA 2000; 97:9070-5; PMID:10922061
   PubMed Web of Science ®Google Scholar